HLTH Inc. and GE Healthcare Reveal Healthcare-Themed Art Gallery
The gallery will be a part of the HLTH Europe event and will be open to all attendees.
No More Barriers
Doug Healy
Healthcare brings out the artist in pharma.
HLTH Inc. announced its own art gallery, sponsored by GE HealthCare. In a press release, HLTH Inc. revealed that the gallery will be part of its inaugural HLTH Europe event, which will occur from June 17-20, 2024 in Amsterdam. The gallery will be open throughout the entire event and will be available to all attendees.
In a press release, HLTH Europe’s managing director Katy Fryatt said, “We are thrilled to launch the HLTH Europe Art Gallery with the support of the GE HealthCare team. Art is a powerful medium through which we can share our experiences and connect with each other. We encourage submissions from all stakeholders in the healthcare ecosystem from patient groups to care givers, clinicians and system leaders. The gallery will foster a sense of community among the whole healthcare ecosystem through art. Ultimately, we hope the gallery offers a reminder about why we are coming together at HLTH–for the benefit of patients."
HLTH is accepting submissions for the gallery from HCPs, patients, and caregivers. The gallery will include a variety of mediums, including paintings, digital art, and photography. Attendees of the gallery will also have access to interactive workshops on various visual art methods.
Simon Philip Rost, Chief Marketing Officer Enterprise Imaging, GE HealthCare, says, "We are proud to be part of this initiative at HLTH Europe. We recognise the therapeutic power of art and its contribution to patients' holistic wellbeing and would encourage everyone in the healthcare ecosystem to consider submitting their work. We look forward to providing a creative outlet for patients and healthcare professionals alike later this year in Amsterdam."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
